Skip to main content
OpenTrials

Clinical trial condition

Refractory Anaplastic Large Cell Lymphoma

Explore clinical trials studying Refractory Anaplastic Large Cell Lymphoma. Study availability and eligibility vary by location and protocol.

10 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Refractory Anaplastic Large Cell Lymphoma trial results

Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Medical Center-Parnassus San Francisco, California, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

Conditions
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +40 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details

Related conditions